Drug intelligence / Profile preview

StemRegenin 1

Development stage: Unknown
Modality: Small Molecules
Administration: Ex Vivo (cell Culture Supplement)

Overview

StemRegenin 1 (SR1) is a selective, cell-permeable, small molecule antagonist of the aryl hydrocarbon receptor (AhR). It potently promotes the ex vivo expansion and self-renewal of human hematopoietic stem/progenitor cells, particularly CD34+ cells from peripheral and cord blood. SR1 increases the number of CD34+ cells up to 330-fold and enhances engraftment efficiency, supporting faster neutrophil and platelet recovery after hematopoietic stem cell transplantation. Its primary investigated application is in stem cell expansion for transplantation and regenerative therapies[1][2][3][4][5][7][9].

Other names: 4-(2-((2-(benzo[b]thiophen-3-yl)-9-isopropyl-9H-purin-6-yl)amino)ethyl)phenolLHD-221LHD221LHD 221

Targets

AHR (Aryl hydrocarbon receptor)

Beyond the preview

Go deeper on StemRegenin 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StemRegenin 1.

Explore the full profile